Focus: Sellas Life Sciences is a publicly traded oncology-focused biotech developing cancer immunotherapies, primarily peptide vaccines and engineered T-cell approaches for hematologic malignancies and solid tumors. The company operates at mid-cap biotech scale with a concentrated pipeline centered on Galinpepimut-S.
Profile data last refreshed 12h ago · AI intelligence enriched 3w ago
No open roles listed right now. Follow Sellas Life Sciences Group to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from Sellas Life Sciences Group's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Sellas Life Sciences Group
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
A Sellas immunotherapy study, long delayed, will end in failure - STAT
A Sellas immunotherapy study, long delayed, will end in failure STAT
SELLAS Life Sciences to Present Preclinical Data on SLS009 - GlobeNewswire
SELLAS Life Sciences to Present Preclinical Data on SLS009 GlobeNewswire
SLS Stock Rises Overnight: Healthcare Execs Tout AML Drug As ‘Game Changer’ Ahead Of Final Trial Trigger - Stocktwits
SLS Stock Rises Overnight: Healthcare Execs Tout AML Drug As ‘Game Changer’ Ahead Of Final Trial Trigger Stocktwits
Sellas Life (SLS) Falls 13% as Firm Still Mum on ALM Drug Candidate - Yahoo Finance
Sellas Life (SLS) Falls 13% as Firm Still Mum on ALM Drug Candidate Yahoo Finance
Sellas Life Sciences Group Inc (SLS) Peer Comparison – Compare with Others - Value Research
Sellas Life Sciences Group Inc (SLS) Peer Comparison – Compare with Others Value Research
SELLAS Life Sciences Jumps 300% YTD as FDA Approval of Rival Pancreatic Cancer Pill Fuels Speculation - finance.biggo.com
SELLAS Life Sciences Jumps 300% YTD as FDA Approval of Rival Pancreatic Cancer Pill Fuels Speculation finance.biggo.com
Showing 6 of 10 news items
No open positions listed yet. Check their careers page directly.
Based on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
REGAL: galinpepimut-S vs. best available therapy as maintenance therapy for acute myeloid leukemia in second remission.
The pharmacodynamic and mechanistic foundation for the antineoplastic effects of GFH009, a potent and highly selective CDK9 inhibitor for the treatment of hematologic malignancies.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo